Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-08-14 8:12 pm Sale | 2024-08-12 | 13D | Addex Therapeutics Ltd ADXN | Growth Equity Opportunities Fund IV, LLC | 0 0.000% | -6,624,600 (Position Closed) | Filing History |
| 2024-08-05 9:00 pm Sale | 2024-08-01 | 13D | Addex Therapeutics Ltd ADXN | Growth Equity Opportunities Fund IV, LLC | 6,624,600 5.100% | -1,080,000 (-14.02%) | Filing History |
| 2023-12-08 2:11 pm Purchase | 2023-11-27 | 13D | Addex Therapeutics Ltd ADXN | Growth Equity Opportunities Fund IV, LLC | 7,704,600 6.400% | 7,704,600 (New Position) | Filing History |
| 2023-11-29 4:00 pm Purchase | 2023-11-27 | 13D | Addex Therapeutics Ltd ADXN | Dyer Timothy Mark | 16,863,355 14.160% | 16,863,355 (New Position) | Filing History |
| 2023-04-10 4:06 pm Unchanged | 2023-04-04 | 13D | Addex Therapeutics Ltd ADXN | Growth Equity Opportunities Fund IV, LLC | 385,230 8.500% | 0 (Unchanged) | Filing History |
| 2023-04-05 4:00 pm Unchanged | 2023-04-04 | 13D | Addex Therapeutics Ltd ADXN | Dyer Timothy Mark | 492,766 11.090% | 0 (Unchanged) | Filing History |
| 2023-03-31 4:00 pm Unchanged | 2023-03-30 | 13D | Addex Therapeutics Ltd ADXN | Dyer Timothy Mark | 492,766 12.180% | 0 (Unchanged) | Filing History |
| 2023-02-16 2:49 pm Sale | 2022-12-31 | 13G | Addex Therapeutics Ltd ADXN | ARMISTICE CAPITAL LLC | 33,765 4.990% | -168,158 (-83.28%) | Filing History |
| 2023-02-14 12:30 pm Sale | 2022-12-31 | 13G | Addex Therapeutics Ltd ADXN | CAXTON CORP | 35,942 0.900% | -79,782 (-68.94%) | Filing History |
| 2023-02-14 11:53 am Purchase | 2022-12-31 | 13G | Addex Therapeutics Ltd ADXN | ARMISTICE CAPITAL LLC | 201,923 4.970% | 170,283 (+538.19%) | Filing History |
| 2023-02-07 6:08 pm Sale | 2022-12-30 | 13G | Addex Therapeutics Ltd ADXN | GOLDMAN SACHS GROUP INC GS | 103 0.000% | -150,246 (-99.93%) | Filing History |
| 2023-02-06 4:32 pm Sale | 2022-12-31 | 13G | Addex Therapeutics Ltd ADXN | New Leaf Biopharma Opportunities I L.P. | 115,815 3.000% | -2,500 (-2.11%) | Filing History |
| 2022-11-28 3:19 pm Unchanged | 2022-11-22 | 13D | Addex Therapeutics Ltd ADXN | Growth Equity Opportunities Fund IV, LLC | 385,230 9.700% | 0 (Unchanged) | Filing History |
| 2022-11-23 06:00 am Unchanged | 2022-11-14 | 13D | Addex Therapeutics Ltd ADXN | Dyer Timothy Mark | 492,766 13.540% | 0 (Unchanged) | Filing History |
| 2022-11-09 4:00 pm Purchase | 2022-10-26 | 13D | Addex Therapeutics Ltd ADXN | Dyer Timothy Mark | 492,766 20.010% | 269,741 (+120.95%) | Filing History |
| 2022-08-23 5:18 pm Unchanged | 2022-07-26 | 13D | Addex Therapeutics Ltd ADXN | Growth Equity Opportunities Fund IV, LLC | 385,230 15.100% | 0 (Unchanged) | Filing History |
| 2022-08-05 06:01 am Purchase | 2022-07-26 | 13D | Addex Therapeutics Ltd ADXN | Dyer Timothy Mark | 223,025 8.400% | 41,476 (+22.85%) | Filing History |
| 2022-02-18 4:54 pm Unchanged | 2022-02-11 | 13G | Addex Therapeutics Ltd ADXN | New Leaf Biopharma Opportunities I L.P. | 118,315 6.200% | 0 (Unchanged) | Filing History |
| 2022-02-14 6:33 pm Purchase | 2021-12-31 | 13G | Addex Therapeutics Ltd ADXN | ARMISTICE CAPITAL LLC | 31,640 9.990% | 31,640 (New Position) | Filing History |
| 2022-02-14 4:07 pm Sale | 2021-12-31 | 13G | Addex Therapeutics Ltd ADXN | CAXTON CORP | 115,724 6.000% | -90 (-0.08%) | Filing History |